COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Sector

Healthcare

Industry

Medical - Care Facilities

CEO

Nath, Kabir

Employees

166

Website

compasspathways.com

IPO Date

2020-09-18

Headquarters

33 Broadwick Street, London, Greater London, W1F 0DQ, United Kingdom

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

COMPASS Pathways CMPS

COMPASS Pathways Earnings Call Summary

COMPASS Pathways Earnings

Transcripts

Events

About COMPASS Pathways plc

COMPASS Pathways
CMPS